A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults

NCT04505098 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

39600

Enrollment

OTHER

Sponsor class

Stopped The study was suspended by the IRB of record and subsequently terminated

Conditions

Covid19
Atherosclerosis
Cardiovascular Diseases
Upper Respiratory Tract Infections

Interventions

DRUG: Icosapent ethyl

Sponsor

Kaiser Permanente

Collaborators

[object Object]